Page 256 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 256
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0785 FIRST REAL CLINICAL PRACTICE DATA IN SPAIN ON
SOFOSBUVIR, SIMEPREVIR AND DACLATASVIR IN
POST-TRANSPLANT HCV RECURRENCE: THE HEPATIC
REGISTRY EXPERIENCE
Martín Prieto*, María Carlota Londoño, Juan Manuel Pascasio,
Magdalena Salcedo, Javier Crespo, José Luis Montero, Isolina Baños,
Inmaculada Fernández, Carmen Vinaixa, Carlos Fernández-Carrillo,
José Luis Calleja, Xavier Forns, Spain
P0786 100% SVR12 WITH LEDIPASVIR/SOFOSBUVIR±RIBAVIRIN
FOR 12 WEEKS IN JAPANESE PATIENTS WITH
ePOSTERS CHRONIC GENOTYPE 1 HEPATITIS C VIRUS WHO
PREVIOUSLY FAILED THERAPY WITH PROTEASE
INHIBITOR+PEGYLATED INTERFERON A+RIBAVIRIN
Masao Omata*, Tetsuo Takehara, Osamu Yokosuka, Naoya Sakamoto,
Masaaki Korenagai, Hitoshi Mochizuki, Kunio Nakane,
Hirayuki Enomoto, Mikio Yanase, Hidenori Toyoda, Fusao Ikeda,
Takuya Genda, Takeji Umemura, Hiroshi Yatsuhashi, Tatusya Ide,
Nobuo Toda, Kazushige Nirei,Yoshiyuki Ueno,Yoichi Nishigaki,
Shampa De-Oertel, Bing Gao, Hadas Dvory-Sobol, Akinobu Ishizaki,
Masa Omote, Phillip S. Pang, Steven J. Knox, William T. Symonds,
John G. McHutchison, Namiki Izumi, Masahi Mizokami, Japan
P0787 COMPARISON OF SOFOSBUVIR +/- SIMEPREVIR IN
HETEROGENEOUS, REAL-WORLD POPULATIONS OF
HCV PATIENTS OVER 70 YEARS OF AGE VS YOUNGER HCV
PATIENTS; DATA FROM THE TRIO NETWORK
Naoky Tsai*, Kris Kowdley, Bruce Bacon, Steven Flamm, Eric Lawitz,
Scott Milligan, Zobair Younossi, Douglas Dieterich, The United States
P0788 ESTIMATING THE COST-EFFECTIVENESS OF
DACLATASVIR PLUS SOFOSBUVIR IN TREATMENT-
NAÏVE, TREATMENT-EXPERIENCED AND INTERFERON-
INELIGIBLE/INTOLERANT PATIENTS WITH ADVANCED
CHRONIC HEPATITIS C GENOTYPE 1 INFECTION
Phil McEwan*, Samantha Webster, Thomas Ward, Anupama Kalsekar,
Yong Yuan, Michael Brenner, The United Kingdom
256 The International Liver Congress™ 2015 • ILC Programme
P0785 FIRST REAL CLINICAL PRACTICE DATA IN SPAIN ON
SOFOSBUVIR, SIMEPREVIR AND DACLATASVIR IN
POST-TRANSPLANT HCV RECURRENCE: THE HEPATIC
REGISTRY EXPERIENCE
Martín Prieto*, María Carlota Londoño, Juan Manuel Pascasio,
Magdalena Salcedo, Javier Crespo, José Luis Montero, Isolina Baños,
Inmaculada Fernández, Carmen Vinaixa, Carlos Fernández-Carrillo,
José Luis Calleja, Xavier Forns, Spain
P0786 100% SVR12 WITH LEDIPASVIR/SOFOSBUVIR±RIBAVIRIN
FOR 12 WEEKS IN JAPANESE PATIENTS WITH
ePOSTERS CHRONIC GENOTYPE 1 HEPATITIS C VIRUS WHO
PREVIOUSLY FAILED THERAPY WITH PROTEASE
INHIBITOR+PEGYLATED INTERFERON A+RIBAVIRIN
Masao Omata*, Tetsuo Takehara, Osamu Yokosuka, Naoya Sakamoto,
Masaaki Korenagai, Hitoshi Mochizuki, Kunio Nakane,
Hirayuki Enomoto, Mikio Yanase, Hidenori Toyoda, Fusao Ikeda,
Takuya Genda, Takeji Umemura, Hiroshi Yatsuhashi, Tatusya Ide,
Nobuo Toda, Kazushige Nirei,Yoshiyuki Ueno,Yoichi Nishigaki,
Shampa De-Oertel, Bing Gao, Hadas Dvory-Sobol, Akinobu Ishizaki,
Masa Omote, Phillip S. Pang, Steven J. Knox, William T. Symonds,
John G. McHutchison, Namiki Izumi, Masahi Mizokami, Japan
P0787 COMPARISON OF SOFOSBUVIR +/- SIMEPREVIR IN
HETEROGENEOUS, REAL-WORLD POPULATIONS OF
HCV PATIENTS OVER 70 YEARS OF AGE VS YOUNGER HCV
PATIENTS; DATA FROM THE TRIO NETWORK
Naoky Tsai*, Kris Kowdley, Bruce Bacon, Steven Flamm, Eric Lawitz,
Scott Milligan, Zobair Younossi, Douglas Dieterich, The United States
P0788 ESTIMATING THE COST-EFFECTIVENESS OF
DACLATASVIR PLUS SOFOSBUVIR IN TREATMENT-
NAÏVE, TREATMENT-EXPERIENCED AND INTERFERON-
INELIGIBLE/INTOLERANT PATIENTS WITH ADVANCED
CHRONIC HEPATITIS C GENOTYPE 1 INFECTION
Phil McEwan*, Samantha Webster, Thomas Ward, Anupama Kalsekar,
Yong Yuan, Michael Brenner, The United Kingdom
256 The International Liver Congress™ 2015 • ILC Programme
